CHC Healthcare Group (TPE:4164)
24.35
-0.65 (-2.60%)
Nov 6, 2026, 1:30 PM CST
CHC Healthcare Group Revenue
CHC Healthcare Group had revenue of 1.16B TWD in the quarter ending September 30, 2026, with 5.57% growth. This brings the company's total for the last twelve months to 4.71B, up 11.83% year-over-year. In the year 2025, CHC Healthcare Group had annual revenue of 4.40B with 22.15% growth. That makes CHC Healthcare Group the 20,045th largest company in the world by revenue and 762nd in Taiwan.
Revenue (ttm)
4.71B
Revenue Growth
+11.83%
P/S Ratio
1.00
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.72B
Revenue by Geography
- Taiwan 4.33B 98.4%
- China 63.50M 1.4%
- Others 8.70M 0.2%
Fiscal year ended Dec 31, 2025 See the full CHC Healthcare Group breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.40B | 797.71M | 22.15% |
| Dec 31, 2024 | 3.60B | -276.56M | -7.13% |
| Dec 31, 2023 | 3.88B | 902.79M | 30.35% |
| Dec 31, 2022 | 2.97B | 534.79M | 21.92% |
| Dec 31, 2021 | 2.44B | -115.35M | -4.51% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 20.75B |
| Cenra | 8.44B |
| Bionime | 1.72B |
| Medigen Biotechnology | 1.27B |
| LIWANLI Innovation | 473.18M |
| Ever Fortune.AI | 382.65M |
| Caliway Biopharmaceuticals | 29.39M |
| Heron Neutron Medical | 11.69M |